European Equities Traded in the US as American Depositary Receipts Move Higher in Thursday Trading

MT Newswires Live06-20

European equities traded in the US as American depositary receipts were trending moderately higher late Thursday morning, rising 0.62% to 1,426.64 on the S&P Europe Select ADR Index.

From continental Europe, the gainers were led by oil and gas company Eni (E), which rose 2.4% and then biopharmaceutical firm DBV Technologies (DBVT), which added 2.1%. They were followed by petroleum refiner Equinor (EQNR) and electronics company Philips (PHG), which were up 1.8% and 1.7%, respectively.

The decliners from continental Europe were led by biopharmaceutical companies Cellectis (CLLS) and Genfit (GNFT), which fell 2.5% and 2%, respectively. They were followed by biopharmaceutical company Grifols (GRFS) and medical device maker EDAP TMS (EDAP), which were down 1.5% and 1.3%, respectively.

From the UK and Ireland, the gainers were led by software firm Endava (DAVA) and biopharmaceutical firm Akari Therapeutics (AKTX), which climbed 8.1% and 3.9%, respectively. Biopharmaceutical firm NuCana (NCNA) was up 2.7% and telecommunications operator Vodafone Group (VOD) added 2.1%.

The decliners from the UK and Ireland were led by biotech firm Trinity Biotech (TRIB), which fell 2.9%, followed by biopharmaceutical company Verona Pharma (VRNA) and construction materials supplier CRH (CRH), which were both down 2.2%. Biopharmaceutical firm Mereo BioPharma (MREO) was off 1.8%.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment